Radius Planning Pivotal Trial of Cannabidiol RAD011

Radius Planning Pivotal Trial of Cannabidiol RAD011

282326

Radius Planning Pivotal Trial of Cannabidiol RAD011

Radius Health has acquired the development and commercialization rights to a synthetic oral cannabidiol therapy known as RAD011, with plans to start a pivotal Phase 2/3 clinical trial in Prader-Willi syndrome (PWS) this year. Having finalized its acquisition deal with Benuvia Therapeutics, the company expects to initiate the trial in the second half of 2021 following discussions with the U.S. Food and Drug Administration (FDA). “RAD011 has the potential for broad clinical applicability. We intend…

You must be logged in to read/download the full post.